Form 4: Solid Biosciences COO David Howton Reports Stock Transactions

Solid Biosciences' Chief Operating Officer, David Howton, reported the acquisition of shares through restricted stock unit vesting and the sale of shares to cover withholding taxes.

Summary

• David Howton, Chief Operating Officer of Solid Biosciences, reported transactions involving the company's stock.
• On December 2, 2024, Mr. Howton acquired 13,051 shares of common stock through the vesting of restricted stock units (RSUs).
• Also on December 2, 2024, Mr. Howton disposed of 20,735 shares of common stock.
• On December 3, 2024, Mr. Howton sold 5,072 shares of common stock at a price of $5.5986 per share.
• The sale of 5,072 shares was to cover withholding taxes related to the vesting of the RSUs and was not a discretionary trade.
• Following these transactions, Mr. Howton beneficially owns 15,663 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions related to stock vesting and tax obligations, which is neutral in sentiment.

Management Comments

• The sale of shares was to cover withholding taxes following the vesting of the previously granted RSUs.
• The sale does not represent a discretionary trade made by Mr. Howton.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the stock ownership of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The vesting schedule of the RSUs, with 25% vesting annually over four years, is a common practice for equity compensation.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine insider activity.

Key Dates

Keywords

Solid Biosciences, stock transactions, Form 4, David Howton, restricted stock units, RSU, insider trading, share sale, vesting